Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JBIO Jade Biosciences	$7.92 -1.4%	$8.71	$6.57 ▼ $105.00	$258.41M	1.03	163,663 shs	43,651 shs
LIAN LianBio	$0.05 +0.4%	$0.20	$0.27 ▼ $4.99	$5.51M	0.23	1.04 million shs	134,127 shs
ONCT Oncternal Therapeutics	$0.53	$0.53	$0.53 ▼ $7.17	$1.56M	1.18	99,758 shs	N/A
PLRZ Polyrizon	$1.05 -0.5%	$1.00	$0.55 ▼ $1,200.00	$6.26M	N/A	3.13 million shs	150,183 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JBIO Jade Biosciences	+1.65%	+9.10%	-3.02%	+802,999,900.00%	+802,999,900.00%
LIAN LianBio	-10.88%	-10.88%	-10.88%	-85.89%	-84.74%
ONCT Oncternal Therapeutics	0.00%	0.00%	0.00%	0.00%	-88.03%
PLRZ Polyrizon	+2.94%	+1.94%	-31.82%	+1.94%	+104,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JBIO Jade Biosciences	2.0955 of 5 stars	3.5	0.0	0.0	0.0	2.9	1.7	0.0
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCT Oncternal Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JBIO Jade Biosciences	3.00	Buy	$16.00	102.02% Upside
LIAN LianBio	0.00	N/A	N/A	N/A
ONCT Oncternal Therapeutics	2.00	Hold	$2.00	279.79% Upside
PLRZ Polyrizon	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONCT, JBIO, PLRZ, and LIAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00
7/14/2025	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/16/2025	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.18 per share	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
ONCT Oncternal Therapeutics	$790K	1.97	N/A	N/A	$10.19 per share	0.05
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$315.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JBIO Jade Biosciences	-$69.63M	-$30.33	N/A	∞	N/A	N/A	-51.96%	-47.65%	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
ONCT Oncternal Therapeutics	-$39.48M	-$11.69	N/A	N/A	N/A	-1,599.95%	-177.58%	-131.30%	N/A
PLRZ Polyrizon	-$1.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ONCT, JBIO, PLRZ, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	JBIO Jade Biosciences	-$0.43	-$0.86	-$0.43	-$0.86	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
ONCT Oncternal Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JBIO Jade Biosciences	N/A	10.31	10.31
LIAN LianBio	N/A	10.06	10.06
ONCT Oncternal Therapeutics	N/A	2.39	2.39
PLRZ Polyrizon	N/A	10.16	10.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JBIO Jade Biosciences	N/A
LIAN LianBio	74.85%
ONCT Oncternal Therapeutics	16.05%
PLRZ Polyrizon	N/A

Insider Ownership

Company	Insider Ownership
JBIO Jade Biosciences	24.90%
LIAN LianBio	7.59%
ONCT Oncternal Therapeutics	11.20%
PLRZ Polyrizon	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JBIO Jade Biosciences	20	32.63 million	24.50 million	N/A
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
ONCT Oncternal Therapeutics	30	2.96 million	2.63 million	No Data
PLRZ Polyrizon	N/A	5.99 million	N/A	N/A

ONCT, JBIO, PLRZ, and LIAN Headlines

Recent News About These Companies

Polyrizon Regains Nasdaq Compliance

August 14, 2025 | msn.com

Polyrizon Ltd. Regains Compliance with Nasdaq Listing Requirements

August 14, 2025 | quiverquant.comQ

Polyrizon Regains Compliance with Nasdaq Listing Requirements

August 14, 2025 | globenewswire.com

Polyrizon Ltd. Announces Special General Meeting for September 2025

July 31, 2025 | tipranks.com

Polyrizon stock soars after promising nasal allergy blocker test results

July 23, 2025 | in.investing.com

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

July 22, 2025 | globenewswire.com

Polyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings Panel

July 15, 2025 | finanznachrichten.de

Polyrizon retains Nasdaq listing following hearings panel

July 15, 2025 | msn.com

Polyrizon Retains Nasdaq Listing Following Hearings Panel

July 15, 2025 | globenewswire.com

Polyrizon’s nasal drug delivery system shows promising results

June 14, 2025 | uk.investing.com

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...

June 12, 2025 | bakersfield.comB

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

June 12, 2025 | globenewswire.com

Polyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution Concerns

May 23, 2025 | quiverquant.comQ

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025 | globenewswire.com

Polyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025

May 22, 2025 | tipranks.com

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025 | globenewswire.com

Polyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant Exercises

May 14, 2025 | tipranks.com

Polyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025 | finanznachrichten.de

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025 | globenewswire.com

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

May 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCT, JBIO, PLRZ, and LIAN Company Descriptions

Jade Biosciences NASDAQ:JBIO

$7.92 -0.11 (-1.37%)

As of 03:46 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

LianBio NASDAQ:LIAN

$0.05 +0.00 (+0.39%)

As of 08/26/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Oncternal Therapeutics NASDAQ:ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Polyrizon NASDAQ:PLRZ

$1.04 -0.01 (-0.48%)

As of 03:50 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time